Aevi Genomic's AEVI-001 flunks mid-stage ADHD study

|About: Aevi Genomic Medicine,... (GNMX)|By:, SA News Editor

A Phase 2 clinical trial, ASCEND, evaluating Aevi Genomic Medicine's (NASDAQ:GNMX) lead candidate AEVI-001 in children aged 6 - 17 with attention deficit hyperactivity disorder (ADHD) failed to achieve the primary in either Part A or Part B after six weeks of treatment.

The company plans to downsize in order to extend its cash runway. At the end of December 2018, it had ~$5M in net working capital.

Previously: Aevi Genomic's lead product candidate flunks ADHD study; shares plummet 56% (March 20, 2017)

Subscribe for full text news in your inbox